The epidermal growth factor receptor 2 her2 is a tyrosine kinase overexpressed in nearly 20% to 25% of invasive breast cancers. Adotrastuzumab emtansine targets hepatocytes via human. Although there are currently other antiher2 agents available e. Ado trastuzumab emtansine tdm1 is an antibodydrug conjugate adc approved for the treatment of her2positive metastatic breast cancer. Trastuzumab 440 mg20 ml en ampula oncologia info medicamento. Trastuzumab mechanism of action and use in clinical practice. Trastuzumab mechanism of action and use in clinical practice to the editor.
Rather than too few patients and events1, low efficacy is the likelier causeof lackingsignificant. In patients with her2positive metastatic breast cancer, pertuzumab added to trastuzumab and docetaxel has been shown to significantly prolong both progressionfree survival and overall survival. It consists of trastuzumab, a humanized mab directed against her2, and a microtubule inhibitor, dm1, conjugated to trastuzumab. Uncertainty over theoptimal duration of adjuvant trastuzumab therapy 5 july 20071extends to optimal sequencingandlongterm outcomes. Trastuzumab is a humanized monoclonal antibody that targets her2. Trastuzumab, a recombinant antibody targeting her2, was the first biological drug approved for the treatment of her2positive bc. Nov 08, 2019 provides accurate and independent information on more than 24,000 prescription drugs, overthecounter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Pdf dual her2 targeting with trastuzumab and liposomal. Dual her2 targeting with trastuzumab and liposomalencapsulated doxorubicin mm 302 demonstrates synergistic antitumor activity in breast and gastric cancer.